7. REFERENCES

1. Barnes, N. M.; Sharp, T. A review of central 5-HT receptors and their function. *Neuropharmacol*, **1999**, *38*, 1083-1152.
2. Barnes, N. M.; Neumaier, J. F. Neuronal 5-HT receptors and SERT. *Tocris. Biosci. Sci. Rev*, **2011**, *34*, 1-15.
3. Manocha, M.; Khan, W. I. Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. *Clin. Transl. Gastroenterol*, **2012**, *3*, e13.
4. Duerschmied, D.; Bode, C. The role of serotonin in haemostasis. *Hamostaseologie*, **2009**, *29*, 356-359.
5. Chase, T. N.; Murphy, D. L. Serotonin and central nervous system function. *Annu. Rev. Pharmacol*, **1973**, *13*, 181-197.
6. Lee, J.; Jung, M. E.; Lee, J. 5-HT_{2C} receptor modulators: a patent survey. *Expert. Opin. Ther.Pat*, **2010**, *20*, 1429-1455.
7. Dawson, L. A.; Bromidge, S. M. 5-HT_1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders. *Curr. Top. Med. Chem*, **2008**, *8*, 1008-1023.
8. Green, A. R. Neuropharmacology of 5-hydroxytryptamine. *Br. J. Pharmacol*, **2006**, *147* Suppl 1, S145-152.
9. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol. Biochem. Behav*, **2002**, *71*, 533-554.
10. Roth, B. L.; Willins, D. L.; Kristiansen, K.; Kroeze, W. K. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. *Pharmacol. Ther*, **1998**, *79*, 231-257.
11. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). *Pharmacol. Rev*, **1994**, *46*, 157-203.
12. Burns, C. M.; Chu, H.; Rueter, S. M.; Hutchinson, L. K.; Canton, H.; Sanders-Bush, E.; Emeson, R. B. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. *Nature*, **1997**, *387*, 303-308.
13. Rang, H. Rang and Dale's Pharmacology, 6th. Edinburgh: Churchill Livingstone 2007.

14. Stamford, J. A.; Davidson, C.; McLaughlin, D. P.; Hopwood, S. E. Control of dorsal raphe 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality? *Trends. Neurosci*, **2000**, *23*, 459-465.
15. Gaddum, J. H.; Picarelli, Z. P. Two kinds of tryptamine receptor. *Br. J. Pharmacol. Chemother*, **1957**, *12*, 323-328.
16. Hannon, J.; Hoyer, D. Molecular biology of 5-HT receptors. *Behav. Brain. Res*, **2008**, *195*, 198-213.
17. Park, C. M.; Kim, S. Y.; Park, W. K.; Park, N. S.; Seong, C. M. Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT_{2C} receptor antagonists. *Bioorg. Med. Chem. Lett*, **2008**, *18*, 3844-3847.
18. Leysen, J. E. 5-HT_2 receptors. *Curr. Drug. Targets. CNS. Neurol. Disord.* 2004, 3, 11-26.
19. Landolt, H. P.; Wehrle, R. Antagonism of serotonergic 5-$HT_{2A/2C}$ receptors: mutual improvement of sleep, cognition and mood? *Eur. J. Neurosci*, **2009**, *29*, 1795-1809.
20. Giorgetti, M.; Tecott, L. H. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. *Eur. J. Pharmacol*, **2004**, *488*, 1-9.
21. Fletcher, P. J.; Tampakeras, M.; Sinyard, J.; Slassi, A.; Isaac, M.; Higgins, G. A. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice. *Neuropharmacol*, **2009**, *57*, 259-267.
22. Barnes, N. M.; Hales, T. G.; Lummis, S. C.; Peters, J. A. The 5-HT_3 receptor--the relationship between structure and function. *Neuropharmacol*, **2009**, *56*, 273-284.
23. Boess, F. G.; Beroukhim, R.; Martin, I. L. Ultrastructure of the 5-HT_3 receptor. *J. Neurochem*, **1995**, *64*, 1401-1405.
24. Weiss, B.; Mertz, A.; Schrock, E.; Koenen, M.; Rappold, G. Assignment of a human homolog of the mouse Htr3 receptor gene to chromosome 11q23.1-q23.2. *Genomics*, **1995**, *29*, 304-305.
25. Pratt, G. D.; Bowery, N. G.; Kilpatrick, G. J.; Leslie, R. A.; Barnes, N. M.; Naylor, R. J.; Jones, B. J.; Nelson, D. R.; Palacids, J. M.; Slater, P.; et al. Consensus meeting agrees distribution of 5-HT_3 receptors in mammalian hindbrain. *Trends Pharmacol. Sci*, **1990**, *11*, 135-137.
26. Barnes, J. M.; Barnes, N. M.; Costall, B.; Ironside, J. W.; Naylor, R. J. Identification and characterisation of 5-HT_3 recognition sites in human brain tissue. *J. Neurochem*, **1989**, *53*, 1787-1793.

27. Wolf, H. Preclinical and clinical pharmacology of the 5-HT_3 receptor antagonists. *Scand J. Rheumatol. Suppl*, **2000**, *113*, 37-45.
28. De Deurwaerdere, P.; Stinus, L.; Spampinato, U. Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT_3 receptors. *J. Neurosci*, **1998**, *18*, 6528-6538.
29. Martin, K. F.; Hannon, S.; Phillips, I.; Heal, D. J. Opposing roles for 5-HT_{1B} and 5-HT_3 receptors in the control of 5-HT release in rat hippocampus in vivo. *Br. J. Pharmacol*, **1992**, *106*, 139-142.
30. Claeysen, S.; Sebben, M.; Becamel, C.; Bockaert, J.; Dumuis, A. Novel brain-specific 5-HT_4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. *Mol. Pharmacol*, **1999**, *55*, 910-920.
31. Varnas, K.; Halldin, C.; Pike, V. W.; Hall, H. Distribution of 5-HT4 receptors in the postmortem human brain--an autoradiographic study using [125I]SB 207710. *Eur. Neuropsychopharmacol*, **2003**, *13*, 228-234.
32. Grailhe, R.; Waeber, C.; Dulawa, S. C.; Hornung, J. P.; Zhuang, X.; Brunner, D.; Geyer, M. A.; Hen, R. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. *Neuron*, **1999**, *22*, 581-591.
33. Matthes, H.; Boschert, U.; Amlaiky, N.; Grailhe, R.; Plassat, J. L.; Muscatelli, F.; Mattei, M. G.; Hen, R. Mouse 5-hydroxytryptamine A and 5-hydroxytryptamine B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. *Mol. Pharmacol*, **1993**, *43*, 313-319.
34. Bonasera, S. J.; Chu, H. M.; Brennan, T. J.; Tecott, L. H. A null mutation of the serotonin 6 receptor alters acute responses to ethanol. *Neuropsychopharmacol*, **2006**, *31*, 1801-1813.
35. Neumaier, J. F.; Sexton, T. J.; Yracheta, J.; Diaz, A. M.; Brownfield, M. Localization of 5-HT(7) receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. *J. Chem. Neuroanat*, **2001**, *21*, 63-73.
36. Heidmann, D. E.; Szot, P.; Kohen, R.; Hamblin, M. W. Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing. *Neuropharmacol*, **1998**, *37*, 1621-1632.
37. Krobert, K. A.; Levy, F. O. The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects. *Br J Pharmacol*, **2002**, *135*, 1563-1571.
38. Bray, G. A. Obesity: the disease. *J. Med. Chem*, **2006**, *49*, 4001-4007.

39. Flegal, K. M.; Carroll, M. D.; Ogden, C. L.; Johnson, C. L. Prevalence and trends in obesity among US adults, 1999-2000. *JAMA*, **2002**, *288*, 1723-1727.
40. Doslikova, B.; Garfield, A. S.; Shaw, J.; Evans, M. L.; Burdakov, D.; Billups, B.; Heisler, L. K. 5-HT_{2C} receptor agonist anorectic efficacy potentiated by 5-HT1B receptor agonist coapplication: an effect mediated via increased proportion of pro-opiomelanocortin neurons activated. *J. Neurosci*, **2013**, *33*, 9800-9804.
41. Halford, J. C.; Harrold, J. A.; Lawton, C. L.; Blundell, J. E. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. *Curr. Drug Targets*, **2005**, *6*, 201-213.
42. Blundell, J. E.; Latham, C. J. Characterisation of adjustments to the structure of feeding behaviour following pharmacological treatment: effects of amphetamine and fenfluramine and the antagonism produced by pimozide and methergoline. *Pharmacol. Biochem. Behav*, **1980**, *12*, 717-722.
43. Monck, N. J.; Kennett, G. A. 5-HT_{2C} ligands: recent progress. *Prog. Med. Chem*, **2008**, *46*, 281-390.
44. Nielsen, J. A.; Chapin, D. S.; Johnson, J. L., Jr.; Torgersen, L. K. Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. *Am. J. Clin. Nutr*, **1992**, *55*, 185S-189S.
45. Barnes, N. M.; Neumaier, J. F. Neuronal 5-HT receptors and SERT. *Tocris. Biosci. Sci. Rev*, **2014**, *34*, 1-15.
46. Kimura, Y.; Naitou, Y.; Wanibuchi, F.; Yamaguchi, T. 5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats. *Eur. J. Pharmacol*, **2008**, *589*, 157-162.
47. Finberg, J. P.; Vardi, Y. Inhibitory effect of 5-hydroxytryptamine on penile erectile function in the rat. *Br. J. Pharmacol*, **1990**, *101*, 698-702.
48. Esen, A. A.; Gidener, S.; Guler, C.; Guven, H.; Kirkali, Z. Contractility changes of the deep dorsal penile vein due to serotonin. *J. Urol*, **1997**, *158*, 234-237.
49. Feijo Fde, M.; Bertoluci, M. C.; Reis, C. [Serotonin and hypothalamic control of hunger: a review]. *Rev. Assoc. Med. Bras*, **2011**, *57*, 74-77.
50. Bishop, M. J.; Nilsson, B. M. New 5-HT_{2C} receptor agonists. *Expert. Opin. Ther. Pat*, **2003**, *13*, 1691-1705.
51. O'Neil, R. Role of the $5HT_{2C}$ receptor in regulation of metabolism and mesolimbic dopamine. *Vanderbilt Reviews Neurosci*, **2010**, *2*, 19-24.

52. Davies, P. A.; Pistis, M.; Hanna, M. C.; Peters, J. A.; Lambert, J. J.; Hales, T. G.; Kirkness, E. F. The 5-HT_{3B} subunit is a major determinant of serotonin-receptor function. *Nature*, **1999**, *397*, 359-363.
53. Dubin, A. E.; Huvar, R.; D'Andrea, M. R.; Pyati, J.; Zhu, J. Y.; Joy, K. C.; Wilson, S. J.; Galindo, J. E.; Glass, C. A.; Luo, L.; Jackson, M. R.; Lovenberg, T. W.; Erlander, M. G. The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. *J. Biol. Chem*, **1999**, *274*, 30799-30810.
54. Kim, G. W.; Lin, J. E.; Valentino, M. A.; Colon-Gonzalez, F.; Waldman, S. A. Regulation of appetite to treat obesity. *Expert Rev. Clin. Pharmacol*, **2011**, *4*, 243-259.
55. Brobeck, J. R. Mechanism of the development of obesity in animals with hypothalamic lesions. *Physiol. Rev*, **1946**, *26*, 541-559.
56. Anand, B. K.; Brobeck, J. R. Hypothalamic control of food intake in rats and cats. Yale *J. Biol. Med*, **1951**, *24*, 123-140.
57. Sclafani, A. Neural pathways involved in the ventromedial hypothalamic lesion syndrome in the rat. *J. Comp. Physiol. Psychol*, **1971**, *77*, 70-96.
58. Fan, W.; Boston, B. A.; Kesterson, R. A.; Hruby, V. J.; Cone, R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. *Nature*, **1997**, *385*, 165-168.
59. Huszar, D.; Lynch, C. A.; Fairchild-Huntress, V.; Dunmore, J. H.; Fang, Q.; Berkemeier, L. R.; Gu, W.; Kesterson, R. A.; Boston, B. A.; Cone, R. D.; Smith, F. J.; Campfield, L. A.; Burn, P.; Lee, F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell*, **1997**, *88*, 131-141.
60. Porter, R. H.; Benwell, K. R.; Lamb, H.; Malcolm, C. S.; Allen, N. H.; Revell, D. F.; Adams, D. R.; Sheardown, M. J. Functional characterization of agonists at recombinant human 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C} receptors in CHO-K1 cells. *Br. J. Pharmacol*, **1999**, *128*, 13-20.
61. Joseph, A. K.; Lawrence, R. M. Process for producing anorexia. *US 3253989 A*, **1966**.
62. Nilsson, B. M. 5-Hydroxytryptamine2C (5-HT2C) receptor agonists as potential antiobesity agents. *J. Med. Chem*, **2006**, *49*, 4023-4034.
63. Adams, D. R.; Bentley, J. M.; Roffey, J. R. A.; Hamlyn, R. J.; Gaur, S.; Duncton, M. A. J.; Davidson, J. E. P.; Bickerdike, M. J.; Cliffe, I. A.; Mansell, H. L. Pyrroloindoles, pyridoindoles and azepinoindoles as 5-HT_{2C} agonists. *US 6433175 B1*, **2002**.

64. Bos, M.; Jenck, F.; Martin, J. R.; Moreau, J. L.; Sleight, A. J.; Wichmann, J.; Widmer, U. Novel agonists of $5HT_{2C}$ receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. *J. Med. Chem*, **1997**, *40*, 2762-2769.
65. Nichols, D. E.; Lloyd, D. H.; Johnson, M. P.; Hoffman, A. J. Synthesis and serotonin receptor affinities of a series of enantiomers of alpha-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin $5\text{-}HT_{1B}$ receptors. *J. Med. Chem*, **1988**, *31*, 1406-1412.
66. Jonathan Mark Bentley, M. J. B., Paul Hebeisen, Guy Anthony Kennett, Sean Lightowler, Patrizio Mattei, Jacques Mizrahi, Timothy James Morley, Jean-Marc Plancher, Hans Richter, Stephan Roever, Sven Taylor, Steven Paul Vickers. Indole derivatives and their use as $5\text{-}HT_{2B}$ and $5\text{-}HT_{2C}$ receptor ligands. *WO 2002051844 A1*, **2002**.
67. Adams David Reginald, D. C. E., Roffey Jonathan Richard Anthon. Composes chimiques iii. *WO 2000012482 A2*, **2000**.
68. Bentley, J. M.; Hebeisen, P.; Taylor, S. Aza-indolyl derivatives for treating obesity. *US 6583134 B2*, **2003**.
69. Boes, M.; Wichmann. *J. Chem. Abstr*, **1995** p 339731.
70. Martin, J. R.; Bos, M.; Jenck, F.; Moreau, J.; Mutel, V.; Sleight, A. J.; Wichmann, J.; Andrews, J. S.; Berendsen, H. H.; Broekkamp, C. L.; Ruigt, G. S.; Kohler, C.; Delft, A. M. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. *J. Pharmacol. Exp. Ther*,**1998**, *286*, 913-924.
71. Clifton, P. G.; Lee, M. D.; Dourish, C. T. Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat. *Psychopharmacol (Berl)*, **2000**, *152*, 256-267.
72. Hester Jr, J. B. Anorexigenic compositions comprising 6-alkyl-1, 2, 3, 4, 5, 6-hexahydroazepino 4, 5-indoles as active ingredient and process of treatment. *US 3676558 A*, **1972**.
73. Gallant, D. M.; Bishop, M. P.; Bishop, G.; O'Meallie, L. U-22,394A: a controlled evaluation in chronic schizophrenic patients. *Curr. Ther. Res Clin. Exp*, **1967**, *9*, 579-581.

74. Jackson B Hester Jr, B. N. R., E Jon Jacobsen, Michael Dalton Ennis, Brad A Acker, Velde Susan L Vander,. Composes d'azepinoindole tetracyclique utilises comme ligands recepteurs de 5-HT. *WO 2000064899 A1*, **2000**.
75. Ennis, M. D.; Hoffman, R. L.; Ghazal, N. B.; Olson, R. M.; Knauer, C. S.; Chio, C. L.; Hyslop, D. K.; Campbell, J. E.; Fitzgerald, L. W.; Nichols, N. F.; Svensson, K. A.; McCall, R. B.; Haber, C. L.; Kagey, M. L.; Dinh, D. M. 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists. *Bioorg. Med. Chem. Lett*, **2003**, *13*, 2369-2372.
76. Brian Smith, J. S., $5HT_{2c}$ receptor modulators. *WO 2003086306 A3*, **2003**.
77. Smith, B. M.; Smith, J. M.; Tsai, J. H.; Schultz, J. A.; Gilson, C. A.; Estrada, S. A.; Chen, R. R.; Park, D. M.; Prieto, E. B.; Gallardo, C. S.; Sengupta, D.; Dosa, P. I.; Covel, J. A.; Ren, A.; Webb, R. R.; Beeley, N. R.; Martin, M.; Morgan, M.; Espitia, S.; Saldana, H. R.; Bjenning, C.; Whelan, K. T.; Grottick, A. J.; Menzaghi, F.; Thomsen, W. J. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin $5\text{-}HT_{2C}$ receptor agonist for the treatment of obesity. *J. Med. Chem*, **2008**, *51*, 305-313.
78. Smith, B.; James, T.; Rita, C. N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of $5HT_{2C}$ receptor associated diseases. *US 20070179155 A1*, **2004**.
79. Brian M. Smith, V. J. S., Rena Hayashi, Jason B. Ibarra, Jeffrey A. Schultz, Scott A. Estrada. N-Biaryl andN-arylheteroaryl piperazine derivatives as modulator of the $5HT_{2C}$ receptor useful for the treatment of disorders related thereto. *WO06065600*, **2006**.
80. Ramamoorthy, S. P. [1,4]diazepino[6,7,1-ij]quinoline derivatives as anti psychotic and antiobesity agents. *WO 2003091250 A1*, **2003**.
81. Junya Shirai, T. K., Hiroyuki Nagamiya, Izumi Kamo. Fused heterocyclic compound and use thereof. *WO 2007132841 A1*, **2007**.
82. Araldi, G., Bischoff, A., Diep, N., Pyridoazepine derivatives, *WO07140213*, **2007**.
83. Sun, G., Slassi, A., Isaac, M., Quach, T., Xin, T., He, Z., Higgins, G., Tetrahydro-5H-pyrido [2,3-*d*]azepines as $5\text{-}HT_{2C}$ ligands. *WO08009125*, **2008**.
84. Slassi, A., Isaac, M., Xin, T., Higgins, G., He, Z., Sun, G., Quach, T., Compounds with activity at the $5\text{-}HT_{2C}$ receptor. *WO09079765*, **2009**.
85. Krull, O.; Wunsch, B. Synthesis and structure/NMDA receptor affinity relationships of 1-substituted tetrahydro-3-benzazepines. *Bioorg. Med. Chem*, **2004**, *12*, 1439-1451.

86. Krieger, C.; Lanius, R. A.; Pelech, S. L.; Shaw, C. A. Amyotrophic lateral sclerosis: the involvement of intracellular Ca2+ and protein kinase C. *Trends. Pharmacol. Sci*, **1996**, *17*, 114-120.

87. Berg, K. A.; Harvey, J. A.; Spampinato, U.; Clarke, W. P. Physiological relevance of constitutive activity of 5-HT_{2A} and 5-HT_{2C} receptors. *Trends Pharmacol. Sci*, **2005**, *26*, 625-630.

88. Rajkumar, R.; Pandey, D. K.; Mahesh, R.; Radha, R. 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT_{2A} receptors: proposal of a modified rodent antidepressant assay. *Eur. J. Pharmacol*, **2009**, *608*, 32-41.

89. Hackler, E. A.; Turner, G. H.; Gresch, P. J.; Sengupta, S.; Deutch, A. Y.; Avison, M. J.; Gore, J. C.; Sanders-Bush, E. 5-HT_{2C} receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. *J. Pharmacol. Exp. Ther*, **2007**, *320*, 1023-1029.

90. Harada, K.; Aota, M.; Inoue, T.; Matsuda, R.; Mihara, T.; Yamaji, T.; Ishibashi, K.; Matsuoka, N. Anxiolytic activity of a novel potent serotonin 5-HT_{2C} receptor antagonist FR260010: a comparison with diazepam and buspirone. *Eur. J. Pharmacol*, **2006**, *553*, 171-184.

91. Kuznetsova, E. G.; Amstislavskaya, T. G.; Shefer, E. A.; Popova, N. K. Effect of 5-HT_{2C} receptor antagonist RS 102221 on mouse behavior. *Bull. Exp. Biol. Med*, **2006**, *142*, 76-79.

92. Tecott, L. H.; Sun, L. M.; Akana, S. F.; Strack, A. M.; Lowenstein, D. H.; Dallman, M. F.; Julius, D. Eating disorder and epilepsy in mice lacking 5-HT_{2C} serotonin receptors. *Nature*, **1995**, *374*, 542-546.

93. Heisler, L. K.; Jobst, E. E.; Sutton, G. M.; Zhou, L.; Borok, E.; Thornton-Jones, Z.; Liu, H. Y.; Zigman, J. M.; Balthasar, N.; Kishi, T.; Lee, C. E.; Aschkenasi, C. J.; Zhang, C. Y.; Yu, J.; Boss, O.; Mountjoy, K. G.; Clifton, P. G.; Lowell, B. B.; Friedman, J. M.; Horvath, T.; Butler, A. A.; Elmquist, J. K.; Cowley, M. A. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. *Neuron*, **2006**, *51*, 239-249.

94. Halford, J. C.; Harrold, J. A.; Boyland, E. J.; Lawton, C. L.; Blundell, J. E. Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. *Drugs*, **2007**, *67*, 27-55.

95. Garfield, A. S.; Heisler, L. K. Pharmacological targeting of the serotonergic system for the treatment of obesity. *J. Physiol*, **2009**, *587*, 49-60.
96. Higgs, S.; Cooper, A. J.; Barnes, N. M. Reversal of sibutramine-induced anorexia with a selective 5-HT_{2C} receptor antagonist. *Psychopharmacol (Berl)*, **2011**, *214*, 941-947.
97. Bagdy, G.; Makara, G. B. Paraventricular nucleus controls 5-HT_{2C} receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. *Eur. J. Pharmacol*, **1995**, *275*, 301-305.
98. Boothman, L. J.; Allers, K. A.; Rasmussen, K.; Sharp, T. Evidence that central 5-HT_{2A} and 5-$HT_{2B/C}$ receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. *Br. J. Pharmacol*, **2003**, *139*, 998-1004.
99. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. *Pharmacol. Ther*, **2006**, *110*, 135-370.
100. Dremencov, E.; El Mansari, M.; Blier, P. Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. *J. Psychiatry Neurosci*, **2009**, *34*, 223-229.
101. Sotty, F.; Folgering, J. H.; Brennum, L. T.; Hogg, S.; Mork, A.; Hertel, P.; Cremers, T. I. Relevance of dorsal raphe nucleus firing in serotonin 5-HT_{2C} receptor blockade-induced augmentation of SSRIs effects. *Neuropharmacol*, **2009**, *57*, 18-24.
102. Chagraoui, A.; Protais, P.; Filloux, T.; Mocaer, E. Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT_{2C} receptors in Wistar rats. *Psychopharmacol (Berl)*, **2003**, *170*, 17-22.
103. Pozzi, L.; Acconcia, S.; Ceglia, I.; Invernizzi, R. W.; Samanin, R. Stimulation of 5-hydroxytryptamine (5-HT_{2C}) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. *J. Neurochem*, **2002**, *82*, 93-100.
104. Armarego, W. L.; Christina, L. Chai. Purification Of Laboratory Chemicals 7E, Elsevier Science **2013**.
105. Ma, C.; Cho, S. D.; Falck, J.; Shin, D. S. One-Pot Synthesis of Pyridazino [1, 4] oxazin-3-ones. *Synthetic. Commun*, **2004**, *34*, 1399-1405.
106. Prill, A. h. S. a. e. j. N-Substituted-amides1. *J. Am. Chem. Soc*, **1956**, *78*, 6123–6127.
107. Smith, B. M.; Smith, J. M.; Tsai, J. H.; Schultz, J. A.; Gilson, C. A.; Estrada, S. A.; Chen, R. R.; Park, D. M.; Prieto, E. B.; Gallardo, C. S. Discovery and SAR of new

benzazepines as potent and selective 5-HT_{2C} receptor agonists for the treatment of obesity. *Bioorg. Med. Chem. Lett*, **2005**, *15*, 1467-1470.

108. Reddy, D. R.; Iqbal, M. A.; Hudkins, R. L.; Messina-McLaughlin, P. A.; Mallamo, J. P. A simple synthetic protocol for the protection of amides, lactams, ureas, and carbamates. *Tetrahedron Lett*. **2002**, *43*, 8063-8066.
109. Hayakawa, M.; Aoyama, T.; Kobayashi, T.; Takido, T.; Kodomari, M. Synthesis of α-Functionalized Amides by a Ritter Reaction in the Presence of NaHSO4/SiO2. *Synlett*, **2014**, *25*, 2365-2369.
110. Yadav, M.; Gandhi, H.; Naik, P.; Giridhar, R. Revelation on the potency of α1-blockers–parallel blockade of angiotensin II receptor: A new finding. *Pharm. Biol*, **2012**, *50*, 439-442.
111. Porsolt, R. D.; Brossard, G.; Hautbois, C.; Roux, S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. *Curr Protoc Neurosci*. **2001**, Chapter 8, Unit 8 10A.
112. Takao, K.; Miyakawa, T. Light/dark transition test for mice. *J. Vis. Exp*, **2006**.
113. Bonhaus, D.; Weinhardt, K.; Taylor, M.; DeSouza, A.; McNeeley, P.; Szczepanski, K.; Fontana, D.; Trinh, J.; Rocha, C.; Dawson, M. RS-102221: a novel high affinity and selective, 5-HT_{2C} receptor antagonist. *Neuropharmacol*, **1997**, *36*, 621-629.
114. Kuznetsova, E.; Amstislavskaya, T.; Shefer, E.; Popova, N. Effect of 5-HT_{2C} receptor antagonist RS 102221 on mouse behavior. *B. Exp. Bio. Med*, **2006**, *142*, 76-79.
115. Schreiber, R.; De Vry, J. Role of 5-HT_{2C} receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. *Prog. NeurpPsychopharmacol. Biol. Psychiatry*, **2002**, *26*, 441-449.
116. Sotty, F.; Folgering, J. H.; Brennum, L. T.; Hogg, S.; Mørk, A.; Hertel, P.; Cremers, T. I. Relevance of dorsal raphe nucleus firing in serotonin 5-HT_{2C} receptor blockade-induced augmentation of SSRIs effects. *Neuropharmacol*, **2009**, *57*, 18-24.
117. Chagraoui, A.; Protais, P.; Filloux, T.; Mocaër, E. Agomelatine (S 20098) antagonizes the penile erections induced by the stimulation of 5-HT_{2C} receptors in Wistar rats. *Psychopharmacol*, **2003**, *170*, 17-22.
118. Pozzi, L.; Acconcia, S.; Ceglia, I.; Invernizzi, R. W.; Samanin, R. Stimulation of 5-hydroxytryptamine (5-HT_{2C}) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. *J. Neurochem*, **2002**, *82*, 93-100.

119. Mongeau, R.; Martin, C. B.; Chevarin, C.; Maldonado, R.; Hamon, M.; Robledo, P.; Lanfumey, L. 5-HT_{2C} receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. *J. Neurochem*, **2010**, *115*, 438-449.
120. Kim, C.; Speisky, M.; Kharouba, S. Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography: Differential effect of probenecid, haloperidol and yohimbine on the concentrations of biogenic amines and metabolites in various regions of rat brain. *J. Chromatogr. A*, **1987**, *386*, 25-35.
121. Chatterjee, M.; Verma, R.; Ganguly, S.; Palit, G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. *Neuropharmacol*, **2012**, *63*, 1161-1171.